Tresiba FlexTouch (Insulin Degludec) is a foundational therapy commonly used to help with the management of Diabetes Mellitus in adults, adolescents, and children from one year of age. This ultra long-acting insulin is applied across domains where additional symptomatic support for maintaining glycemic control is needed.

This medication is relevant for easing the overall burden of chronic high blood sugar (hyperglycemia) in patients with Type 1 Diabetes and Type 2 Diabetes. It provides continuous, steady background insulin replacement necessary to address symptoms related to systemic imbalance. This action generally assists with maintaining functional stability and contributes to easing the overall symptom load.

A key use is its application in contexts involving the episodic or fluctuating manifestations of blood sugar during fasting and overnight periods. Its sustained profile supports stable glucose levels and contributes to improved comfort by reducing the risk of nocturnal hypoglycemia, a condition marked by heightened physiological stress.

---

Quick Fact: Relief for Systemic Imbalance Symptoms This treatment is used for managing symptoms related to systemic imbalance during fasting and sleep periods.

Tresiba FlexTouch (Insulin Degludec) eligibility is defined by strict regulatory criteria concerning patient condition, age, and delivery system constraints.

---

Populations for Whom Use is Contraindicated

The medicine is contraindicated and must not be used by two groups, as established in the official prescribing information:

• Patients experiencing acute episodes of hypoglycemia (low blood sugar).
• Patients with documented hypersensitivity to insulin degludec or any of the formulation's excipients.

---

Age-Related and Conditional Eligibility

Classification	Eligibility Status as per Regulatory Label
Approved Age Range	Adults, adolescents, and children from the age of 1 year and older with diabetes mellitus.
Not Recommended	Children below the age of 1 year (safety and efficacy not established).
Conditional Use	Patients with renal or hepatic impairment and older adults (ge 65 years old) are eligible, but require intensified glucose monitoring.
Acute Limitation	Not recommended for the treatment of Diabetic Ketoacidosis (DKA).

---

Reproductive and Pen-Specific Restrictions

Use during pregnancy is permitted but requires intensified blood glucose monitoring and control. The official label notes that the FlexTouch pen must never be shared between any patients due to the risk of transmitting blood-borne pathogens.

Interactions with other medicines and products

The official interaction profile for Insulin Degludec (Tresiba FlexTouch) is primarily defined by the pharmacodynamic classification of co-administered agents, which can either potentiate or reduce its blood glucose-lowering effect.

Documented Pharmacodynamic Interactions

Co-administration with medicines such as Monoamine Oxidase Inhibitors (MAOIs), ACE Inhibitors, Salicylates, and Somatostatin Analogs is formally documented to increase the blood glucose lowering effect, thereby increasing the risk of hypoglycemia. Conversely, the co-administration of agents like Corticosteroids, Diuretics, Oral Contraceptives, and Sympathomimetic Agents is documented to decrease the glucose-lowering effect, raising the risk of hyperglycemia.

Specific Combination and Substance Restrictions

The use of Insulin Degludec in combination with Thiazolidinediones (TZDs) is subject to a specific regulatory warning regarding the increased risk of fluid retention, which may lead to or worsen heart failure. The consumption of alcohol (ethanol) is also officially documented to unpredictably increase hypoglycemic risk. Furthermore, regulatory procedural constraints strictly prohibit the solution from being diluted or mixed with any other insulin or solution, or transferred from the FlexTouch pen into a syringe.

Molecular Assembly and Subcutaneous Depot Formation

Tresiba contains insulin degludec, an ultra-long-acting insulin analog. Upon injection, the drug utilizes a unique structure that permits insulin degludec dihexamers to assemble into soluble multi-hexamer chains within the subcutaneous tissue. This physical-chemical mechanism creates a stable depot that provides a basis for an extended duration of action. The protracted release governs the continuous availability of insulin monomers, contributing to sustained insulin receptor engagement.

---

Insulin Receptor Agonism and Glucose Regulation

Insulin degludec acts as an agonist at the human insulin receptor on cell surfaces. Binding to the receptor initiates signaling sequences that modulate intracellular processes. These sequences primarily stimulate peripheral glucose uptake in muscle and adipose tissue, while simultaneously suppressing hepatic glucose production (gluconeogenesis and glycogenolysis) in the liver. This activity modifies key metabolic pathways, resulting in the system-level physiological consequence of decreased plasma glucose concentration.

Using the Tresiba FlexTouch Pen

The Tresiba FlexTouch is a pre-filled, multidose disposable injection pen containing insulin degludec. It is designed to be used with disposable needles. The pen features a push-button mechanism and an internal spring that delivers the dose without the user having to apply manual pressure to the plunger during the injection.

Preparation and Priming

Before each injection, the pen must be prepared to ensure it is functioning correctly and the insulin is clear and colorless. This process involves checking the insulin level and attaching a new, sterile needle. Priming the pen, also known as a flow check, is performed before every injection to remove air bubbles and verify that the needle and pen are working together to deliver the correct amount of medication.

Setting the Dose

The dose is selected by turning a dose selector dial. The FlexTouch pen displays the number of units in a digital dose counter window. The dial can be turned forward or backward to reach the required dose before the injection is administered. The pen is designed to prevent the selection of a dose larger than the number of units remaining in the reservoir.

Injection Sites

Insulin degludec is administered as a subcutaneous injection. Common areas for injection include the abdomen, the upper arms, or the thighs. It is a standard practice to rotate injection sites within the chosen area to reduce the risk of changes to the fatty tissue under the skin, such as thickening or pitting.

Maintenance and Storage

The FlexTouch pen should be stored according to specific temperature requirements to maintain the stability of the insulin. When not in use, the pen cap should be kept on to protect the insulin from light. Used needles must be removed after every injection and disposed of in an appropriate sharps container; the pen should never be stored with a needle attached to prevent leakage or air from entering the cartridge.

Research evidence / Overview of Studies for Tresiba FlexTouch

The clinical research program for Tresiba FlexTouch, which contains insulin degludec, consists of a series of large-scale studies. These studies were designed to examine clinical measures related to glycemic status, or blood sugar control, and included other long-acting insulins as active comparators. This summary describes the types of research conducted and outlines the patterns observed in the studies, while clearly highlighting areas where research is still limited or ongoing.

Evidence for Use in Type 1 Diabetes Mellitus (T1DM)

Research for Type 1 Diabetes (T1DM) primarily included Randomized Controlled Trials (RCTs) and crossover studies. The trials primarily measured Glycosylated Hemoglobin ( HbA1c) levels, which are used to monitor glycemic status over time. Research also focused heavily on measures describing episodic or acute changes in blood sugar, specifically monitoring the frequency and rates of overall, severe, and nocturnal hypoglycemia occurrence.

Findings describe patterns observed in these studies where measurements of HbA1c were consistent with the prespecified non-inferiority criteria compared to other basal insulins. Research also describes patterns where the documentation of severe and nocturnal hypoglycemia occurrence was less frequent in the comparison group. Long-term data regarding clinical endpoints are not fully established, as many core efficacy studies had follow-up durations that were limited to 26 or 52 weeks.

---

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

For Type 2 Diabetes (T2DM), a broad range of research was conducted, including RCTs and a dedicated Cardiovascular Outcomes Trial (CVOT). The core studies monitored changes in HbA1c and Fasting Plasma Glucose (FPG), and included the assessment of hypoglycemia event rates.

Findings from the primary analysis of the CVOT reported that the occurrence of Major Adverse Cardiovascular Event (MACE) was not associated with an increased risk when compared to the active comparator. Data also show patterns related to severe and nocturnal hypoglycemia occurrence where the reported rate was less frequent in the comparison group.

---

Evidence in Special Populations and Areas of Uncertainty

Research explored clinical measures for this medicine in specific subgroups, including pediatric patients (children and adolescents as young as 1 year old) with both Type 1 and Type 2 Diabetes. The high cardiovascular risk population with Type 2 Diabetes was a specific focus of the CVOT, meaning the results for that long-term trial apply only to the populations studied who met those particular cardiovascular risk criteria.

Many key studies were open-label, a design limitation where the lack of blinding is a documented risk for observation bias. Data for certain subgroups, such as patients with specific levels of renal or hepatic impairment, remain insufficient. Overall, the research provides context about what has been observed so far, but study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Common questions about Tresiba FlexTouch (FAQ)

Q: How long does it take for Tresiba FlexTouch (insulin degludec) to start working?

A: Insulin degludec begins to lower blood sugar levels typically within 30 to 90 minutes after injection. It is an ultra-long-acting insulin, and its effects on blood sugar control are designed to be sustained over a period greater than 40 hours.

---

Q: Can I drink alcohol while taking Tresiba FlexTouch?

A: Consuming alcohol can affect blood sugar levels, potentially increasing the risk of hypoglycemia (low blood sugar) when taking insulin. It is necessary to discuss personal alcohol consumption habits and the management of associated risks with a healthcare provider.

---

Q: What should I do if I miss a dose of Tresiba FlexTouch?

A: If a dose is forgotten, the prescribing information generally advises injecting the missed dose upon discovery, ensuring there is a minimum of 8 hours between the injection of the missed dose and the next scheduled dose. Never use two doses to make up for a missed one. Consulting with a healthcare professional or pharmacist is recommended to review the official instructions for missed doses.

Storage and Disposal of Tresiba FlexTouch

Tresiba FlexTouch (Insulin Degludec) has specific regulatory requirements for storage and disposal to ensure product integrity and safety.

---

Official Storage Conditions

Condition	Requirement
Unopened Pen	Store in a refrigerator between 2 C and 8 C (36 F and 46 F) in the original carton to protect from light.
In-Use Pen	Store at room temperature (up to 30 C or 86 F) or refrigerated. Must be discarded 56 days (8 weeks) after first use.
Prohibited	Do not freeze. Do not use if frozen. Keep away from excessive heat and direct sunlight.

---

Handling and Disposal

Always keep the pen out of the sight and reach of children. Store the pen without a needle attached. Used needles and empty pens must be disposed of immediately in an approved, puncture-resistant sharps disposal container. Loose needles and syringes must not be disposed of in household trash. Unused medication must be discarded according to local requirements.